Zenotech Laboratories Ltd
Zenotech Laboratories Ltd (ZENOTECH) last reported results for the quarter ended Sep 2006, with sales of ₹5.27 crore and net profit of ₹0.73 crore. The stock last traded at ₹42.8, a market capitalisation of ₹261 crore. Over the past 52 weeks the stock has ranged between ₹33.6 and ₹54.1. Figures are as of 6 Oct 2026 and are not real time.
Zenotech Laboratories Ltd share price and key metrics
- Current price
- ₹42.8
- Market cap
- ₹261 cr
- Book value
- ₹15.8
- ROE
- -12.2%
- ROCE
- -9.08%
- Dividend yield
- 0.00%
- 52w high / low
- 54.1/33.6
Metrics as of 6 Oct 2026. Not real time.
Track Zenotech Laboratories Ltd
Cruxal reads every Zenotech Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Zenotech Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -20%
- TTM
- 9%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 29%
- 10 Years
- 1%
- 5 Years
- -3%
- 3 Years
- -12%
- 1 Year
- -20%
- 10 Years
- %
- 5 Years
- -13%
- 3 Years
- -15%
- Last Year
- -12%
Zenotech Laboratories Ltd quarterly results
| ₹ crore | Jun 2006 | Sep 2006 |
|---|---|---|
| Sales | 2.83 | 5.27 |
| Expenses | 4.3 | 3.98 |
| Operating profit | -1.47 | 1.29 |
| OPM % | -51.94% | 24.48% |
| Other income | 0.1 | 0.23 |
| Interest | 0.3 | 0.45 |
| Depreciation | 0.12 | 0.34 |
| Profit before tax | -1.79 | 0.73 |
| Tax % | 0.00% | 0.00% |
| Net profit | -1.79 | 0.73 |
| EPS (₹) | — | 0.14 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Zenotech Laboratories Ltd annual results
| ₹ crore | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Sales | 12 | 13 | 8 | 6 | 7 |
| Operating profit | -3 | -6 | -10 | -18 | -9 |
| OPM % | -20% | -49% | -121% | -292% | -143% |
| Net profit | -4 | 2 | -16 | -18 | -13 |
| EPS (₹) | — | 0.32 | -2.64 | -2.88 | -2.05 |
TTM is the trailing twelve months to the most recent quarter.
Zenotech Laboratories Ltd balance sheet
| ₹ crore | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Equity capital | 16 | 29 | 34 | 34 | 34 |
| Reserves | 6 | 25 | 92 | 74 | 62 |
| Borrowings | 31 | 36 | 19 | 17 | 10 |
| Other liabilities | 21 | 10 | 8 | 5 | 4 |
| Total liabilities | 74 | 100 | 153 | 131 | 111 |
| Fixed assets | 16 | 60 | 61 | 62 | 71 |
| CWIP | 40 | 9 | 15 | 24 | 13 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other assets | 19 | 30 | 77 | 45 | 27 |
| Total assets | 74 | 100 | 153 | 131 | 111 |
As reported by the company. Total assets equal total liabilities by construction.
Zenotech Laboratories Ltd cash flow
| ₹ crore | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Cash from operations | -16 | -7 | -3 | -16 | -10 |
| Cash from investing | -56 | -15 | -67 | 20 | 29 |
| Cash from financing | 74 | 22 | 70 | -4 | -8 |
| Net cash flow | 2 | -0 | -0 | 1 | 11 |
| Free cash flow | -70 | -22 | -13 | -28 | -11 |
| CFO / operating profit | 619% | 109% | 23% | 82% | 102% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Zenotech Laboratories Ltd operating ratios
| Per year | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| ROCE % | — | 2% | -9% | -12% | -9% |
| Debtor days | 145 | 273 | 85 | 36 | 96 |
| Inventory days | 139 | 331 | 575 | 172 | 279 |
| Days payable | 451 | 455 | 421 | 226 | 253 |
| Cash conversion cycle | -167 | 149 | 240 | -18 | 123 |
| Working capital days | 55 | 279 | 196 | 250 | 286 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Zenotech Laboratories Ltd shareholding pattern
Promoters held 68.84% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 68.84% | 68.84% | 68.84% | 68.84% | 68.84% | 68.84% | 68.84% | 68.84% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Government | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% | 0.98% |
| Public | 30.18% | 30.18% | 30.18% | 30.17% | 30.18% | 30.18% | 30.17% | 30.17% |
| No. of shareholders | 10,641 | 10,667 | 10,690 | 10,661 | 10,670 | 10,464 | 10,301 | 10,161 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Zenotech Laboratories Ltd corporate filings
- Intimation of Closure of Trading WindowInsider Trading / SASTlow impact
- Zenotech Laboratories Limited secures shareholder approval for material related party transactions with Sun Pharmaceutical Industries LimitedAGM/EGMmedium impact
Cruxal's analysis: Zenotech Laboratories Limited has successfully concluded its 37th Annual General Meeting…
Read the full analysis - Zenotech Laboratories Reports FY26 Financial Results and AGM Outcome; Revenue Grows 1.5% Amidst Net LossAGM/EGMmedium impact
Cruxal's analysis: Zenotech Laboratories Limited reported FY26 revenue of 39.56 crore, a marginal 1.5%…
Read the full analysis - Zenotech Laboratories Ltd announces 37th Annual General Meeting and e-voting scheduleCompany Updatelow impact
Cruxal's analysis: Zenotech Laboratories Ltd has published a newspaper notice regarding the scheduling of…
Read the full analysis - Zenotech Laboratories Limited Announces 37th AGM and Seeks Approval for ₹200 Crore Material Related Party Transactions with Sun PharmaAGM/EGMmedium impact
Cruxal's analysis: Zenotech Laboratories Limited has scheduled its 37th Annual General Meeting for September…
Read the full analysis - Zenotech Laboratories Ltd releases 2025-26 Annual Report and 37th AGM noticeOtherslow impact
Cruxal's analysis: Zenotech Laboratories has filed its Annual Report for the financial year 2025-26 and…
Read the full analysis - Zenotech Laboratories Ltd: Routine Newspaper Publication of Financial ResultsCompany Updatelow impact
Cruxal's analysis: Zenotech Laboratories Ltd has fulfilled its regulatory obligation under Regulation 30 of…
Read the full analysis - Zenotech Laboratories Limited schedules 37th Annual General Meeting for September 25, 2026AGM/EGMlow impact
Cruxal's analysis: Zenotech Laboratories Limited has formally announced that its 37th Annual General Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.